We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
- Authors
Kim, Seoyoung C.; Sarpatwari, Ameet; Landon, Joan E.; Desai, Rishi J.
- Abstract
The article presents a study related to the utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the U.S. It mentions that several originator tumor necrosis factor inhibitors (TNFi) including adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), and infliximab (Remicade), and 2 infliximab biosimilars like infliximab-dyyb (Inflectra approved in April 2016.
- Subjects
DENMARK; UNITED States; ANTI-inflammatory agents; MEDICAL care costs; MEDICARE; INFLIXIMAB; BIOSIMILARS
- Publication
Arthritis & Rheumatology, 2020, Vol 72, Issue 6, p1036
- ISSN
2326-5191
- Publication type
Article
- DOI
10.1002/art.41201